-
22 votes
-
Searching for Susy Thunder [a famous computer hacker of the 80s]
39 votes -
Discogs’ vibrant vinyl community is shattering
12 votes -
Getty Images CEO Craig Peters has a plan to defend photography from AI | Discussion of Getty's AI image generator and related topics
13 votes -
Reddit is going to let you turn gold into money
61 votes -
YouTube is axing its ad-free Premium Lite subscription plan
54 votes -
Raspberry Pi Foundation announces details of impending release of the Raspberry Pi 5
52 votes -
Spotify (with OpenAI) is going to clone podcasters’ voices — and translate them to other languages
27 votes -
Meta’s AI chatbot plan includes a ‘sassy robot’ for younger users
8 votes -
Google US antitrust trial - judge ordered trial exhibits removed from the web - the Verge responds by publishing them
24 votes -
Neuralink is recruiting subjects for the first human trial of its brain-computer interface
9 votes -
Microsoft leaked its own Xbox documents, court says
21 votes -
This is Microsoft’s new disc-less Xbox Series X design with a new controller
22 votes -
Microsoft documents leak new Bethesda games, including an Oblivion remaster
26 votes -
Phenylephrine, a common decongestant in medicines is no better than a placebo when taken orally, says a US FDA advisory panel
by Wes Davis A key cold medicine ingredient is basically worthless The FDA’s 16-member advisory panel unanimously voted yesterday that oral phenylephrine, a common active ingredient in cold...
by Wes Davis
A key cold medicine ingredient is basically worthless
The FDA’s 16-member advisory panel unanimously voted yesterday that oral phenylephrine, a common active ingredient in cold medications, is no better than a placebo for treating congestion.
Link to the article
The call by the panel sets up potential FDA action that could force the removal of certain over-the-counter medications containing the ingredient — including certain formulations of Mucinex, Sudafed, Tylenol, and NyQuil — from store shelves.
But FDA may hold off for many months, pending contested findings by drug makers and other considerations.Data
Newer data from studies the panel says are more consistent with modern clinical trial standards showed phenylephrine simply “was not significantly different from placebo” in the recommended dosage, including trials from 2007 that the FDA had reviewed when considering the drug after a citizen petition prompted it to do so.
Bioavailability
The panel cited the drug’s low bioavailability, a term referring to qualities that allow the drug to be absorbed by the human body, as the main reason the drug should be removed from the market.
Jennifer Schwartzott said the drug “should have been removed from the market a long time ago,” while Dr. Stephen Clement said that although the drug itself isn’t dangerous, its usage by patients should be considered unsafe because it potentially delays actual treatment of disease symptoms.
Alternative
The panel cited pseudoephedrine as an effective alternative though while it’s technically available without a prescription, you must talk to a pharmacist to get it because, in large quantities, it can be used to make methamphetamines.
50 votes -
Today I learned this weird Windows keyboard shortcut opens LinkedIn
43 votes -
Experts link LastPass security breach to a string of crypto heists
48 votes -
Spotify is pulling select advertising privileges for white noise podcasts in a bid to boost the audio streaming company's annual profits
34 votes -
WhatsApp is working on cross-platform messaging
18 votes -
iPhone 14, 14 Pro owners complain about battery capacity that’s already falling off
36 votes -
After two decades the dominance of Google Search comes into question
85 votes -
Battle Royale, revisited
13 votes -
Saints Row developer Volition permanently shuts down
53 votes -
Apple announces the iPhone 15 launch event
23 votes -
Linus Tech Tips pauses production as controversy swirls
121 votes -
Microsoft to sell off Activision cloud gaming rights to Ubisoft in bid for UK approval
25 votes -
Western Digital refused to answer our questions about its self-wiping SanDisk SSDs. Oh, and it’s also getting sued.
53 votes -
The fight over what’s real (and what’s not) on dissociative identity disorder TikTok
20 votes -
Leaked images reveal Lenovo’s Steam Deck competitor with a hint of the Switch
39 votes -
Twitch will let streamers ban users from watching their streams
15 votes -
The Babylon 5 animated movie is B5: The Road Home, and here’s what it’s about
26 votes -
CNET is deleting old articles to try to improve its Google Search ranking
29 votes -
$5 billion Google lawsuit over ‘Incognito mode’ tracking moves a step closer to trial
58 votes -
Google Messages signs onto cross-platform encrypted group chat standard
53 votes -
What would the internet of people look like now?
39 votes -
The buttons on Zenith’s original ‘clicker’ remote were a mechanical marvel
90 votes -
Donald Glover and his brother, Stephen, are writing Disney Plus’ Lando series
38 votes -
Twitter is now X as the little blue bird disappears
131 votes -
Looking back at the original Chromecast, which just turned ten years old
9 votes -
Sarah Silverman is suing OpenAI and Meta for copyright infringement
57 votes -
Reddit is getting rid of its Gold awards system
88 votes -
Meet Microsoft Office’s new default font: Aptos
43 votes -
US FTC appeals its loss to Microsoft in Activision Blizzard case
23 votes -
Microsoft wins US FTC fight to buy Activision Blizzard
76 votes -
Microsoft’s Activision deal could face ‘new merger investigation,’ UK regulator warns
20 votes -
Instagram’s Twitter competitor, Threads, is available now
77 votes -
Reddit demands moderators remove NSFW labels, or else
113 votes -
The Framework Laptop 16-inch gets extra external snap-on batteries
31 votes -
Who killed Google Reader - a ten year anniversary retrospective discussion
76 votes -
/r/IAmA mods to stop hosting celebrity AMAs, verifying identities, and more
144 votes